About Matrix metalloproteinase-19
Matrix metalloproteinase-19 (MMP19) is a protein
from Homo sapiens identified by UniProt accession
Q99542, 508 residues long.
MolForge cross-references it against 0 known binders and
221 disease associations.
Target properties
| Protein name | Matrix metalloproteinase-19 |
| UniProt accession | Q99542 |
| Gene | MMP19 |
| Organism | Homo sapiens |
| Length | 508 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (221)
Diseases linked to this target (Open Targets).
- Optic neuropathy · score 0.50
- familial cavitary optic disk anomaly · score 0.45
- neuroinflammatory disorder · score 0.31
- neurodegenerative disease · score 0.29
- breast adenocarcinoma · score 0.22
- lung adenocarcinoma · score 0.19
- interstitial lung disease · score 0.11
- non-small cell lung carcinoma · score 0.08
- pulmonary fibrosis · score 0.08
- cancer · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99542-F1 | alphafold | PREDICTED | 79.10 | — |
Amino-acid sequence (508 residues)
MNCQQLWLGF LLPMTVSGRV LGLAEVAPVD YLSQYGYLQK PLEGSNNFKP EDITEALRAF QEASELPVSG QLDDATRARM RQPRCGLEDP FNQKTLKYLL LGRWRKKHLT FRILNLPSTL PPHTARAALR QAFQDWSNVA PLTFQEVQAG AADIRLSFHG RQSSYCSNTF DGPGRVLAHA DIPELGSVHF DEDEFWTEGT YRGVNLRIIA AHEVGHALGL GHSRYSQALM APVYEGYRPH FKLHPDDVAG IQALYGKKSP VIRDEEEEET ELPTVPPVPT EPSPMPDPCS SELDAMMLGP RGKTYAFKGD YVWTVSDSGP GPLFRVSALW EGLPGNLDAA VYSPRTQWIH FFKGDKVWRY INFKMSPGFP KKLNRVEPNL DAALYWPLNQ KVFLFKGSGY WQWDELARTD FSSYPKPIKG LFTGVPNQPS AAMSWQDGRV YFFKGKVYWR LNQQLRVEKG YPRNISHNWM HCRPRTIDTT PSGGNTTPSG TGITLDTTLS ATETTFEY
Explore Matrix metalloproteinase-19 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets